JP Morgan Call 300 AMG 17.01.2025/ DE000JL0RQM0 /
2024-08-28 12:51:47 PM | Chg.-0.01 | Bid10:00:28 PM | Ask10:00:28 PM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
3.99EUR | -0.25% | - Bid Size: - |
- Ask Size: - |
AMGEN INC. DL-... | 300.00 - | 2025-01-17 | Call |
GlobeNewswire
08-15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
08-12
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-08
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
08-08
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
08-05
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
08-01
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
07-22
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
07-02
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...
GlobeNewswire
06-27
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...
GlobeNewswire
06-27
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...
GlobeNewswire
06-25
Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025
GlobeNewswire
06-20
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...